Skip to content

Aura Biosciences, Inc. AURA Other Non-Current Assets

Other Non-Current Assets at other companies

UroGen Pharma logo
UroGen PharmaURGN
$7.49M+1,920%
CG Oncology logo
CG OncologyCGON
$2.68M-89.4%
Relmada Therapeutics, Inc. logo
Relmada Therapeutics, Inc.RLMD
$19.5K-11.3%
Inhibrx Biosciences, Inc. logo
Inhibrx Biosciences, Inc.INBX
$4.38M-35.6%
Nuvation Bio logo
Nuvation BioNUVB
$3.82M-42.2%
Immunome logo
ImmunomeIMNM
$5.36M+23.4%

Other financials

Income statement

See full
Operating income-$34.9M-20.1%
Net income-$33.7M-22.6%
EPS (diluted)-$0.50+9.1%

Balance sheet

See full
Cash & equivalents$84.8M+122%
Total debt$17.0M-7.9%
Total equity$107.2M-16.2%
Total assets$137.7M-11.4%

Cash flow

See full
Operating cash flow-$29.9M-28.0%
CapEx$102.0K-45.5%
Free cash flow-$30.0M-27.4%

Valuation

See full
Market cap$709.23M+89.4%
Enterprise value$641.43M+80.8%

Returns & leverage

See full
Return on equity-95.6%+222pp
Debt / equity0.2×0.0×
Current ratio7.1×-4.0×

Where this comes from

Reported directly by Aura Biosciences, Inc. in its filing.

Tagged under the XBRL concept us-gaap:OtherAssetsNoncurrent.

The official record: Aura Biosciences, Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Aura Biosciences, Inc.'s other non-current assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Aura Biosciences, Inc.'s other non-current assets?
Aura Biosciences, Inc. (AURA) reported other non-current assets of $517K in Q1 2026.
What is the long-term trend for Aura Biosciences, Inc.'s other non-current assets?
Over 3 years (2022 to 2025), Aura Biosciences, Inc.'s other non-current assets has grown at a 3.6% compound annual growth rate (CAGR), from $423K to $471K.
What does other non-current assets mean?
Long-term assets not classified in specific categories — a catch-all for miscellaneous non-current assets.